Pre-Clinical Studies and Clinical Trials
The CCIR provides the infrastructure and environment that are conducive toward translating discoveries in basic immunology into revolutionary cancer treatments that can be readily tested in a clinical setting. Numerous CCIR investigators are conducting pre-clinical studies and clinical trials to test new or improved forms of cancer immunotherapy. These clinical trials not only serve as avenues for advancing both science and medicine, but they can also represent a profound sense of hope for cancer patients who have limited treatment options.
Chart illustrating progress of CCIR cancer immunotherapies as they advance from pre-clinical studies to each phase of a clinical trial
Links to Information about Clinical Trials
Infusion of CAR T cells: Patients with advanced B cell-lineage lymphoid malignancies (NCT00968760)
Infusion of haploidentical natural killer (NK) cells: Patients with relapsed neuroblastoma (NCT00698009)
Infusion of haploidentical NK cells combined with epratuzumab (CD22-specific monoclonal antibody): Patients with relapsed acute lymphoblastic leukemia (NCT00941928)
TLR agonist plus vaccination with the melanoma-associated peptides gp100 and MAGE-3: Patients with metastatic melanoma with measurable disease, stage IIIC (in transient lesions) or stage IV M1A with disease that includes lesions accessible for biopsies (NCT00960752)
Adoptive T cell transfer plus dendritic cell vaccination: Patients with advanced stage of melanoma (NCT00338377)
Leuprolide plus vaccination with the melanoma-associated peptides gp100 and MAGE-3: Patients with stage IIb-IV melanoma (NCT00254397)
PR1 (leukemia-associated peptide) Vaccine: Patients with chronic myeloid leukemia, acute myeloid leukemia or myelodysplastic syndromes (NCT00004918)
Gp100 (melanoma-associated peptide) Vaccine: Patients with Stage IIb-III or stage IV melanoma (NCT00019682)
Lymphoma Idiotype Vaccine: Patients with follicular B cell Non-Hodgkin's lymphoma (NCT00089115), indolent B cell Non-Hodgkin's lymphoma (NCT00258336) or mantle cell lymphoma (NCT00020215)
Lymphoma Idiotype Vaccine plus GM-CSF: Follicular lymphoma patients undergoing first complete remission (NCT00091676)
